Aernoud Fiolet

287 Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels Supplemental figure 2. Extracellular vesicle NLRP3 protein levels and serum NLRP3 protein levels after one year treatment with colchicine or placebo. EV NLRP3 protein levels and NLRP3 levels in serumwithout EV isolation in patients treated with colchicine compared to placebo. Boxplots represent median with inter quartile range and whiskers show 10-90th percentile. To compare EVNLRP3 protein levels and serumNLRP3 protein levelswe determined these levels in a randomselection (2/3) of patients (n=175). EV NLRP3 protein levels were lower in patients treated with colchicine (n=91) (median 1.30 ng/mL) compared to placebo (n=84) (median 1.73 ng/mL) (difference -0.43 ng/mL, 95% CI -0.60 to -0.13; p <0.005). Serum NLRP3 protein levels in the same patients were not different in patients treated with colchicine (median 5.04 ng/mL) compared to placebo (median 5.14 ng/mL) (difference -0.10 ng/ mL, 95% CI -1.20 to 0.13; p =0.128). NB the panel on the left side shows EVNLRP3 protein levels in the same patients (n=175) in which we measured serum NLRP3 protein levels. Figure 3 in the main paper shows EV NLRP3 protein levels in the total group (n=278). Abbreviations: EV, extracellular vesicle; NLRP3, nucleotide-binding oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3